Seite - 4 - in Cancer Nanotheranostics - What Have We Learnd So Far?

4 March 2016 | Cancer NanotheranosticsFrontiers in Chemistry Table of Contents 05 Editorial: Cancer Nanotheranostics: What Have We Learned So Far? João Conde, Furong Tian, Jesus M. de la Fuente and Pedro V. Baptista 08 Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine João Conde, Jorge T. Dias, Valeria Grazú, Maria Moros, Pedro V. Baptista and Jesus M. de la Fuente 35 Nanomedicines for cancer therapy: State-of-the-art and limitations to pre- clinical studies that hinder future developments Charlene M. Dawidczyk, Luisa M. Russell and Peter C. Searson 48 Gold nanoparticles and their alternatives for radiation therapy enhancement Daniel R. Cooper, Devesh Bekah and Jay L. Nadeau 61 Therapeutic antisense oligonucleotides against cancer: Hurdling to the clinic Pedro M. D. Moreno and Ana P. Pêgo 68 Cancer immunotherapy: Nanodelivery approaches for immune cell targeting and tracking João Conniot, Joana M. Silva, Joana G. Fernandes, Liana C. Silva, Rogério Gaspar, Steve Brocchini, Helena F. Florindo and Teresa S. Barata 95 Biomolecular corona on nanoparticles: A survey of recent literature and its implications in targeted drug delivery Ryan M. Pearson, Vanessa V. Juettner and Seungpyo Hong 102 The application of magnetic nanoparticles for the treatment of brain tumors Keon Mahmoudi and Costas G. Hadjipanayis 107 Molecular imaging of breast cancer: Present and future directions David Alcantara, Manuel Pernia Leal, Irene García-Bocanegra and Maria L. García-Martín 118 A biological perspective toward the interaction of theranostic nanoparticles with the bloodstream – what needs to be considered? Martin J. D. Clift, Jean-François Dechézelles, Barbara Rothen-Rutishauser and Alke Petri-Fink 122 Multifunctional gold nanostars for molecular imaging and cancer therapy Yang Liu, Hsiangkuo Yuan, Andrew M. Fales, Janna K. Register and Tuan Vo-Dinh